{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:19:56Z","timestamp":1790036396864,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.mayocp.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T08:47:40Z","timestamp":1499244460000},"page":"1070-1079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Parkinson Disease and Melanoma"],"prefix":"10.1016","volume":"92","author":[{"given":"Lauren A.","family":"Dalvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gena M.","family":"Damento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara P.","family":"Yawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose S.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mayocp.2017.03.014_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamaoncol.2015.1810","article-title":"Parkinson disease and malignant disease: minding cancer\u2019s own business","volume":"1","author":"Ganguli","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.03.014_bib2","first-page":"556","article-title":"Multiple primary melanoma following administration of levodopa","volume":"93","author":"Skibba","year":"1972","journal-title":"Arch Pathol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.03.014_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1353-8020(03)00040-3","article-title":"Malignant melanoma and levodopa in Parkinson\u2019s disease: causality or coincidence?","volume":"9","author":"Fiala","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"10.1016\/j.mayocp.2017.03.014_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jama.1984.03350080017013","article-title":"Choroidal melanoma and levodopa","volume":"252","author":"Abramson","year":"1984","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.mayocp.2017.03.014_bib5","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0b013e31821e554e","article-title":"Meta-analysis of the relationship between Parkinson disease and melanoma","volume":"76","author":"Liu","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mayocp.2017.03.014_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10886-005-1338-9","article-title":"Involvement of reactive oxygen species generated from melanin synthesis pathway in phytotoxicty of L-DOPA","volume":"31","author":"Hachinohe","year":"2005","journal-title":"J\u00a0Chem Ecol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.03.014_bib7","first-page":"136","article-title":"The biosynthesis of mammalian melanin","volume":"70","author":"Pawelek","year":"1982","journal-title":"Am Sci"},{"issue":"5","key":"10.1016\/j.mayocp.2017.03.014_bib8","first-page":"323","article-title":"Effect of L-dopa on the growth of human melanoma cells in\u00a0vitro","volume":"42","author":"Osman","year":"1987","journal-title":"J\u00a0Pharm Belg"},{"issue":"1-2","key":"10.1016\/j.mayocp.2017.03.014_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/00207459208986663","article-title":"Accelerated growth of malignant melanoma by levodopa in Parkinson\u2019s disease and role of the pineal gland","volume":"63","author":"Sandyk","year":"1992","journal-title":"Int J Neurosci"},{"issue":"3","key":"10.1016\/j.mayocp.2017.03.014_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archneurol.2010.1","article-title":"Increased melanoma risk in Parkinson disease: a prospective clinicopathological study","volume":"67","author":"Bertoni","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.03.014_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.43.4.674","article-title":"Levodopa, melanoma, and Parkinson\u2019s disease","volume":"43","author":"Weiner","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2017.03.014_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/1523-1747.ep12515896","article-title":"The use of L-dopa and carbidopa in metastatic malignant melanoma","volume":"96","author":"Gurney","year":"1991","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.03.014_bib13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/mds.20401","article-title":"Risk of cancer after the diagnosis of Parkinson\u2019s disease: a historical cohort study","volume":"20","author":"Elbaz","year":"2005","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.mayocp.2017.03.014_bib14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjc.6602279","article-title":"Atypical cancer pattern in patients with Parkinson\u2019s disease","volume":"92","author":"Olsen","year":"2005","journal-title":"Br J Cancer"},{"issue":"suppl 13","key":"10.1016\/j.mayocp.2017.03.014_bib15","first-page":"S58","article-title":"Evaluation of Parkinson\u2019s disease (PD) prevalence in patients with malignant melanoma (Poster 22)","volume":"21","author":"Rigel","year":"2006","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.mayocp.2017.03.014_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/mds.25734","article-title":"Malignant melanoma in early-treated Parkinson\u2019s disease: the NET-PD trial","volume":"29","author":"Constantinescu","year":"2014","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.mayocp.2017.03.014_bib17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mds.21273","article-title":"Malignant melanoma in early Parkinson\u2019s disease: the DATATOP trial","volume":"22","author":"Constantinescu","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.mayocp.2017.03.014_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10552-007-9005-9","article-title":"Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson\u2019s disease","volume":"18","author":"Driver","year":"2007","journal-title":"Cancer Causes Control"},{"issue":"5","key":"10.1016\/j.mayocp.2017.03.014_bib19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.ede.0000229445.90471.5e","article-title":"Malignant melanoma and other types of cancer preceding Parkinson disease","volume":"17","author":"Olsen","year":"2006","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.mayocp.2017.03.014_bib20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/jnnp-2014-310239","article-title":"Frequency and profile of Parkinson\u2019s disease prodromi in patients with malignant melanoma","volume":"87","author":"Walter","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.mayocp.2017.03.014_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00001648-200203000-00010","article-title":"Nonfatal cancer preceding Parkinson\u2019s disease: a case-control study","volume":"13","author":"Elbaz","year":"2002","journal-title":"Epidemiology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.03.014_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/bjo.76.4.246","article-title":"Lid melanoma and parkinsonism","volume":"76","author":"Haider","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.03.014_bib23","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(82)34616-3","article-title":"Uveal malignant melanoma and levodopa therapy in Parkinson\u2019s disease","volume":"89","author":"Van Rens","year":"1982","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.03.014_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/scientificamerican1081-54","article-title":"The patient record in epidemiology","volume":"245","author":"Kurland","year":"1981","journal-title":"Sci Am"},{"issue":"3","key":"10.1016\/j.mayocp.2017.03.014_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4065\/71.3.266","article-title":"History of the Rochester Epidemiology Project","volume":"71","author":"Melton","year":"1996","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.mayocp.2017.03.014_bib26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.mayocp.2012.08.012","article-title":"History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population","volume":"87","author":"Rocca","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2017.03.014_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0025-6196(12)60270-5","article-title":"The Olmsted County Benchmark Project: primary study findings and potential implications for corporate America","volume":"67","author":"Campion","year":"1992","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.mayocp.2017.03.014_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0025-6196(12)65531-1","article-title":"A\u00a0community blood pressure survey: Rochester, Minnesota, 1986","volume":"63","author":"Phillips","year":"1988","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2017.03.014_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archneur.60.1.91","article-title":"Survival study of Parkinson disease in Olmsted County, Minnesota","volume":"60","author":"Elbaz","year":"2003","journal-title":"Arch Neurol"},{"issue":"suppl 5","key":"10.1016\/j.mayocp.2017.03.014_bib30","first-page":"39","article-title":"Lewy body dementia and Parkinson\u2019s disease with dementia","volume":"255","author":"Dodel","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.03.014_bib31","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.43.9.1693","article-title":"Risk factors for Parkinson\u2019s disease","volume":"43","author":"Hubble","year":"1993","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.03.014_bib32","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#","article-title":"Environmental, medical, and family history risk factors for Parkinson\u2019s disease: a New England-based case control study","volume":"88","author":"Taylor","year":"1999","journal-title":"Am J Med Genet"},{"issue":"6","key":"10.1016\/j.mayocp.2017.03.014_bib33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.26192","article-title":"Genetic risk and age in Parkinson\u2019s disease: continuum not stratum","volume":"30","author":"Nalls","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.mayocp.2017.03.014_bib34","first-page":"110","volume":"151","author":"Romo-Guti\u00e9rrez","year":"2015","journal-title":"Gac Med Mex"},{"issue":"10","key":"10.1016\/j.mayocp.2017.03.014_bib35","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/ijc.25912","article-title":"The association between Parkinson\u2019s disease and melanoma","volume":"128","author":"Pan","year":"2011","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2017.03.014_bib36","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1200\/JCO.2005.11.108","article-title":"Risk factors and individual probabilities of melanoma for whites","volume":"23","author":"Cho","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.03.014_bib37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp.2003.020982","article-title":"Are men at greater risk for Parkinson\u2019s disease than women?","volume":"75","author":"Wooten","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"16","key":"10.1016\/j.mayocp.2017.03.014_bib38","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1212\/WNL.0b013e3181bd13a1","article-title":"Family history of melanoma and Parkinson disease risk","volume":"73","author":"Gao","year":"2009","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.mayocp.2017.03.014_bib39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","article-title":"Time trends in the incidence of Parkinson disease","volume":"73","author":"Savica","year":"2016","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.03.014_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.mayocp.2012.01.010","article-title":"Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota","volume":"87","author":"Reed","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.mayocp.2017.03.014_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3322\/caac.20141","article-title":"Cancers with increasing incidence trends in the United States: 1999 through 2008","volume":"62","author":"Simard","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.mayocp.2017.03.014_bib42","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.1996.216","article-title":"Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors","volume":"73","author":"Westerdahl","year":"1996","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2017.03.014_bib43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1023\/B:CACO.0000003839.56954.73","article-title":"Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort","volume":"14","author":"Freedman","year":"2003","journal-title":"Cancer Causes Control"},{"issue":"8","key":"10.1016\/j.mayocp.2017.03.014_bib44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/aje\/155.8.732","article-title":"Parkinson\u2019s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake","volume":"155","author":"Checkoway","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.mayocp.2017.03.014_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fphar.2012.00033","article-title":"Aspects of innate immunity and Parkinson\u2019s disease","volume":"3","author":"Huang","year":"2012","journal-title":"Front Pharmacol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617302392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617302392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T11:50:37Z","timestamp":1535629837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617302392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0025619617302392"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.03.014","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson Disease and Melanoma","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}